Triptolide protects against 1-methyl-4-phenyl pyridinium-induced dopaminergic neurotoxicity in rats: Implication for immunosuppressive therapy in Parkinson's disease

Neuroscience Bulletin

Volumn 24, Issue 3, 2008, Pages 133-142

  Gao, Jun Peng ^a   Sun, Shan ^a   Li, Wen Wei ^a   Chen, Yi Ping ^a   Cai, Ding Fang ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Microglia; Neurons; Parkinson's disease; Triptolide

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; APOMORPHINE; BRAIN PROTEIN; CELL MARKER; PROTEIN OX 42; TRIPTOLIDE; TYROSINE 3 MONOOXYGENASE;

AKINESIA; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR DISORDER; CELL ACTIVATION; CELL DEATH; CELL LOSS; CELL VIABILITY; CONTROLLED STUDY; DISEASE MODEL; DOPAMINERGIC NERVE CELL; DRUG EFFECT; DRUG EFFICACY; FORELIMB; IMMUNOSUPPRESSIVE TREATMENT; LOCOMOTION; MALE; MICROGLIA; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; RAT; ROTATION; SCORING SYSTEM; SINGLE DRUG DOSE; SUBSTANTIA NIGRA; VIBRISSA;

1-METHYL-4-PHENYLPYRIDINIUM; ANIMALS; ANTIGENS, CD11B; BIOLOGICAL MARKERS; CELL COUNT; CELL SURVIVAL; DISABILITY EVALUATION; DITERPENES; DOPAMINE; ENCEPHALITIS; EPOXY COMPOUNDS; GLIOSIS; HERBICIDES; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; MALE; MICROGLIA; NEURONS; PARKINSONIAN DISORDERS; PHENANTHRENES; RATS; RATS, SPRAGUE-DAWLEY; SUBSTANTIA NIGRA; TREATMENT OUTCOME; TYROSINE 3-MONOOXYGENASE;

EID: 47649105314     PISSN: 16737067     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12264-008-1225-9     Document Type: Article

References (52)

1. L.M. de Lau M.M. Breteler 2006 Epidemiology of Parkinson's disease Lancet Neurol 5 525 535
2. A.E. Lang A.M. Lozano 1998 Parkinson's disease. First of two parts N Engl J Med 339 1044 1053
3. H.L. Zhang J.J. Wu H.M. Ren J. Wang Y.R. Su Y.P. Jiang 2007 Therapeutic effect of microencapsulated porcine retinal pigmented epithelial cells transplantation on rat model of Parkinson's disease Neurosci Bull 23 137 144
4. W. Poewe 2006 The need for neuroprotective therapies in Parkinson's disease Neurology 66 S2 S9
5. R.A. Hauser T.A. Zesiewicz 2006 Clinical trials aimed at detecting neuroprotection in Parkinson's disease Neurology 66 S58 S68
6. Y. Ouchi E. Yoshikawa Y. Sekine M. Futatsubashi T. Kanno T. Ogusu 2005 Microglial activation and dopamine terminal loss in early Parkinson's disease Ann Neurol 57 168 175
7. Y.S. Kim T.H. Joh 2006 Microglia, major player in the brain inflammation: their roles in the pathogenesis of Parkinson's disease Exp Mol Med 38 333 347
8. P.S. Whitton 2007 Inflammation as a causative factor in the aetiology of Parkinson's disease Br J Pharmacol 150 963 976
9. J.W. Langston L.S. Forno J. Tetrud A.G. Reeves J.A. Kaplan D. Karluk 1999 Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure Ann Neurol 46 598 605
10. P.L. McGeer C. Schwab A. Parent D. Doudet 2003 Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine administration Ann Neurol 54 599 604
11. F. Cicchetti A.L. Brownell K. Williams Y.I. Chen E. Livni O. Isacson 2002 Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging Eur J Neurosci 15 991 998
12. H. Yuan J.C. Zheng P. Liu S.F. Zhang J.Y. Xu L.M. Bai 2007 Pathogenesis of Parkinson's disease: oxidative stress, environmental impact factors and inflammatory processes Neurosci Bull 23 125 130
13. D. Qiu P.N. Kao 2003 Immunosuppressive and anti-inflammatory mechanisms of triptolide, the principal active diterpenoid from the Chinese medicinal herb Tripterygium wilfordii Hook. f Drugs R D 4 1 18
14. J. Ma M. Dey H. Yang A. Poulev R. Pouleva R. Dorn 2007 Antiinflammatory and immunosuppressive compounds from Tripterygium wilfordii Phytochemistry 68 1172 1178
15. Q.Y. Liu T.Y. Chen G.Y. Chen X.L. Shu A. Sun P.C. Ma 2007 Triptolide impairs dendritic cell migration by inhibiting CCR7 and COX-2 expression through PI3-K/Akt and NF-kappa B pathways Mol Immunol 44 2686 2696
16. F.Q. Li X.Z. Lu X.B. Liang H.F. Zhou B. Xue X.Y. Liu 2004 Triptolide, a Chinese herbal extract, protects dopaminergic neurons from inflammation-mediated damage through inhibition of microglial activation J Neuroimmunol 148 24 31
17. H.F. Zhou X.Y. Liu D.B. Niu F.Q. Li Q.H. He X.M. Wang 2005 Triptolide protects dopaminergic neurons from inflammation-mediated damage lipopolysaccharide intranigral induced by injection Neurobiol Dis 18 441 449
18. D.S. Maharaj K.S. Saravanan H. Maharaj K.P. Mohanakumar S. Daya 2004 Acetaminophen and aspirin inhibit superoxide anion generation and lipid peroxidation, and protect against 1-methyl-4-phenyl pyridinium-induced dopaminergic neurotoxicity in rats Neurochem Int 44 355 360
19. Paxinos G, Watson C. The rat brain in stereotaxic coordinates. 5th ed. 2005, Sydney: Elsevier Academic Press.
20. L. Truong H. Allbutt M. Kassiou J.M. Henderson 2006 Developing a preclinical model of Parkinson's disease: a study of behaviour in rats with graded 6-OHDA lesions Behav Brain Res 169 1 9
21. M. Olsson G. Nikkhah C. Bentlage A. Bjorklund 1995 Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test J Neurosci 15 3863 3875
22. J.L. Tillerson A.D. Cohen J. Philhower G.W. Miller M.J. Zigmond T. Schallert 2001 Forced limb-use effects on the behavioral and neurochemical effects of 6-hydroxydopamine J Neurosci 21 4427 4435
23. J.L. Tillerson W.M. Caudle M.E. Reveron G.W. Miller 2003 Exercise induces behavioral recovery and attenuates neurochemical deficits in rodent models of Parkinson's disease Neuroscience 119 899 911
24. Y. Hua T. Schallert R.F. Keep J. Wu J.T. Hoff G. Xi 2002 Behavioral tests after intracerebral hemorrhage in the rat Stroke 33 2478 2484
25. C. Monville E.M. Torres S.B. Dunnett 2005 Validation of the l-dopainduced dyskinesia in the 6-OHDA model and evaluation of the effects of selective dopamine receptor agonists and antagonists Brain Res Bull 68 16 23
26. S. Sun H. Cao M. Han T.T. Li H.L. Pan Z.Q. Zhao 2007 New evidence for the involvement of spinal fractalkine receptor in pain facilitation and spinal glial activation in rat model of monoarthritis Pain 129 64 75
27. A.J. Vaananen P. Rauhala R.K. Tuominen P. Liesi 2006 KDI tripeptide of gamma 1 laminin protects rat dopaminergic neurons from 6-OHDA induced toxicity J Neurosci Res 84 655 665
28. B. Liu J.S. Hong 2003 Role of microglia in inflammation-mediated neurodegenerative diseases: Mechanisms and strategies for therapeutic intervention J Pharmacol Exp Ther 304 1 7
29. + Neuroreport 15 1039 1044
30. R. Deumens A. Blokland J. Prickaerts 2002 Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway Exp Neurol 175 303 317
31. + in sprague-dawley rats: Cellular, molecular and ultrastructural evidences Neurochem Res 32 1238 1247
32. Y. Du Z. Ma S. Lin R.C. Dodel F. Gao K.R. Bales 2001 Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease Proc Natl Acad Sci U S A 98 14669 14674
33. D.C. Wu V. Jackson-Lewis M. Vila K. Tieu P. Teismann C. Vadseth 2002 Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine mouse model of Parkinson disease J Neurosci 22 1763 1771
34. J.W. Langston P. Ballard J.W. Tetrud I. Irwin 1983 Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis Science 219 979 980
35. X.W. Chen S.G. Sun D.B. Cheng Y.Y. Tian 2006 Overexpression of 14-3-3 protein protects pheochromocytoma cells against 1-methyl-4-phenylpyridinium toxicity Neurosci Bull 22 281 287
36. S. Samantaray G. Chandra K.P. Mohanakumar 2003 Calcium channel agonist, (+/-)-Bay K8644, causes a transient increase in striatal monoamine oxidase activity in Balb/c mice Neurosci Lett 342 73 76
37. S. Przedborski M. Vila 2003 The 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine mouse model: a tool to explore the pathogenesis of Parkinson's disease Ann N Y Acad Sci 991 189 198
38. S. Hunot E.C. Hirsch 2003 Neuroinflammatory processes in Parkinson's disease Ann Neurol 53 S49 S58
39. E.C. Hirsch S. Hunot A. Hartmann 2005 Neuroinflammatory processes in Parkinson's disease Parkinsonism Relat Disord 11 S9 S15
40. R. Vijitruth M. Liu D.Y. Choi X.V. Nguyen R.L. Hunter G. Bing 2006 Cyclooxygenase-2 mediates microglial activation and secondary dopaminergic cell death in the mouse MPTP model of Parkinson's disease J Neuroinflammation 3 6
41. S.U. Kim J. de Vellis 2005 Microglia in health and disease J Neurosci Res 81 302 313
42. P. Teismann K. Tieu O. Cohen D.K. Choi D.C. Wu D. Marks 2003 Pathogenic role of glial cells in Parkinson's disease Mov Disord 18 121 129
43. M.B. Youdim E. Grunblatt Y. Levites G. Maor S. Mandel 2002 Early and late molecular events in neurodegeneration and neuroprotection in Parkinson's disease MPTP model as assessed by cDNA microarray; the role of iron Neurotox Res 4 679 689
44. K.B. Goralski K.W. Renton 2004 Brain inflammation enhances 1-methyl-4-phenylpyridinium-evoked neurotoxicity in rats Toxicol Appl Pharmacol 196 381 389
45. X.Z. Zhu X.Y. Li J. Liu 2004 Recent pharmacological studies on natural products in China Eur J Pharmacol 500 221 230
46. P. Teismann K. Tieu D.K. Choi D.C. Wu A. Naini S. Hunot 2003 Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration Proc Natl Acad Sci U S A 100 5473 5478
47. +-induced COX-2 activation and subsequent dopaminergic neurodegeneration FASEB J 19 1134 1136
48. F.S. Shie K.S. Montine R.M. Breyer T.J. Montine 2005 Microglial EP2 is critical to neurotoxicity from activated cerebral innate immunity Glia 52 70 77
49. Z.H. Feng T.G. Wang D.D. Li P. Fung B.C. Wilson B. Liu 2002 Cyclooxygenase-2-deficient mice are resistant to 1-methyl-4-phenyl1,2,3,6- tetrahydropyridine-induced damage of dopaminergic neurons in the substantia nigra Neurosci Lett 329 354 358
50. R. Sanchez-Pernaute A. Ferree O. Cooper M. Yu A.L. Brownell O. Isacson 2004 Selective COX-2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson's disease J Neuroinflammation 1 6
51. Y.Q. Dai D.Z. Jin X.Z. Zhu D.L. Lei 2006 Triptolide inhibits COX-2 expression via NF-kappa B pathway in astrocytes Neurosci Res 55 154 160
52. A. Schober 2004 Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP Cell Tissue Res 318 215 224